drugset / Trial / NCT00873002
Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery
Phase 1
Terminated
3 enrolled
Case Comprehensive Cancer Center
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Panobinostat and sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of liver cancer by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of panobinostat when given together with sorafenib in treating patients with liver cancer that is metastatic and/or cannot be removed by surgery.
Timeline
- Start
- 2009-03
- Primary completion
- 2010-05
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Panobinostat | Small molecule | 7.5 mg/m2 | Intravenous |
| Comparator | Panobinostat | Small molecule | 10 mg/m2 | Intravenous |
| Comparator | Panobinostat | Small molecule | 15 mg/m2 | Intravenous |
| Comparator | Panobinostat | Small molecule | 20 mg/m2 | Intravenous |
| Comparator | Panobinostat | Small molecule | 30 mg/m2 | Intravenous |
| Comparator | Sorafenib | Small molecule | 400 mg | Oral |